EMJ Hematology 13 [Supplement 3] . 2025

In this issue

In this insightful new interview, key opinion leader Talha Munir reviews the current landscape of chronic lymphocytic leukaemia (CLL), and delves into interim analysis results from the AMPLIFY study with acalabrutinib–venetoclax ± obinutuzumab, 5-year data from the SEQUOIA study with zanubrutinib, and updated data from the BRUIN CLL-321 study with pirtobrutinib.